Floatz logo

Capecitabine

pMMR

First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the pMMR cohort.

Asset / SponsorPhaseRating
Irinotecan
Replimune, Inc.
Phase 2CCC
Serplulimab
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Atezolizumab
Replimune, Inc.
Phase 2CCC
Dfn-15
Zhejiang University
Phase 2CCC
Fruquintinib
China Medical University, China
Phase 2CCC

View all 12 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →